Not yet a member?
Print This Post
view / write comments
That short month of February makes it so that March really sneaks up on you! We’re just a few days from March and our first of several upcoming webinars I need to tell people about.
The first will actually be on Monday, March 1st (just 4 days from now), with Dr. Jared Weiss from University of Pennsylvania joining me at 8 PM EST/5PM PST for a discussion of two very different but timely topics. First, Dr. Weiss will cover the controversial and completely open question of what role EGFR inhibitors might play in early stage NSCLC, or whether we should even be talking about and checking for EGFR mutations in patients who don’t have advanced non-small cell lung cancer (NSCLC) (where most of the research and discussion has been concentrated). Next, I’ll turn to a debate that has been ongoing for decades in lung cancer: should the minority of patients with very localized small cell lung cancer (SCLC) undergo surgery? A very recent review of results from a large database put this topic back in the lung cancer news. So should SCLC ever be managed surgically? I’ll try to highlight the pros and cons.
Dr. Weiss and I will discuss our own perspectives on both of these issues and also leave time for questions from participants in the live online event. If you’re interested, you can’t beat the price of registration (free, though your financial support is very helpful), which is through this link: Register for the March 1 program with myself and Dr. Weiss
Oh, but it doesn’t end there. We received an educational grant from Eli Lilly in support of a couple of additional March webinars from terrific lung cancer leaders to cover very central topics in managing advanced NSCLC. On March 10th (again, 8 PM EST/5 PM PST), Dr. Suresh Ramalingam, medical oncologist and head of the Thoracic Oncology Program at Emory University in Atlanta, GA will cover “Personalized Therapy for First Line Treatment of Advanced NSCLC”. This approximately hour-long program will cover issues such as NSCLC histology (tumor subtype) safety concerns with anti-angiogenic agents, and the emerging work on molecular markers and how these factors lead to individualized recommendations for patients initiating treatment for advanced NSCLC, including an approximately 40-45 minute presentation, followed by time for questions from participants in the live program. Register for March 10th webinar with Dr. Ramalingam on Personalized Therapy Recommendations for First Line Treatment of Advanced NSCLC
A week later (Wednesday, March 17th at 8 PM EST/5 PM PST), medical oncologist Dr. Mark Socinski, who leads the world-renowned lung cancer program at the University of North Carolina at Chapel Hill, will cover “Optimizing Timing and Choice of Treatment after First Line Treatment of Advanced NSCLC”. Like the first line discussion by Dr. Ramalingam, this will be an approximately 40-45 minute presentation followed by Q&A, and Dr. Socinski will focus on the evidence supporting which agents are our strongest treatment options and how we might consider the question of whether patients should transition straight from first line to later treatment or whether a break from treatment might be a good idea. Register for March 17th webinar with Dr. Socinski on Timing and Treatment Choice after First Line Treatment for Advanced NSCLC.
Registration for each of these live events is limited, and we also know that the timing doesn’t work well for everyone who might want to be there, so all of these activities will be turned into podcast materials for people to refer to at any time in the future.
Related posts:
Related posts brought to you by Yet Another Related Posts Plugin.
Posted in: Webinars email to a friend
Print This Post
No Comments
Login (Must Be Logged In To Comment)